Alnylam and Regeneron report updated positive Phase I results of Alzheimer’s drug

Alnylam Pharmaceuticals announced today updated positive interim results of a Phase I study of pipeline drug ALN-APP for the treatment of Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA).